Merck says experimental RSV treatment protected infants in trial, paving way for potential approval - CNBC
- Merck says experimental RSV treatment protected infants in trial, paving way for potential approval CNBC
- Merck's Posts More Positive Clesrovimab RSV Candidate Study Data MarketWatch
- IDWeek: Clesrovimab reduces RSV disease, hospitalization in healthy infants Contemporary Pediatrics
- Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants Yahoo Finance
- Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study Reuters